Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001)

3-year results from an open-label, phase 1 study

Natasha B. Leighl, Matthew D. Hellmann, Rina Hui, Enric Carcereny, Enriqueta Felip, Myung Ju Ahn, Joseph Paul Eder, Ani S. Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew Gubens, Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001. Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated randomisation schedule at cohort-dependent ratios, and a further four cohorts were assigned to a pembrolizumab dose without randomisation. We present 3-year outcomes for the full analysis set of patients who received at least one dose of study treatment, pooled for all pembrolizumab doses. The primary efficacy endpoint was proportion of patients with objective response, analysed here as investigator-assessed response according to immune-related response criteria. Secondary efficacy endpoints included overall survival, duration of response, and progression-free survival. Safety endpoints included incidence of adverse events. This study is registered at ClinicalTrials.gov, number NCT01295827, and is ongoing. Findings: Between May 8, 2012 and July 13, 2014, 550 patients (101 treatment naive and 449 previously treated) were enrolled. Median follow-up was 34·5 months at data cutoff (Sept 1, 2016). At 36 months, investigator-assessed objective response according to immune-related response criteria was achieved for 41 of 101 treatment naive patients (41% [95% CI 30·9–50·8]; median duration of response was 16·7 months [95% CI 12·6–not reached]) and 102 of 449 previously treated patients (23% [18·9–26·9]; 33·3 ([22·5–not reached]). The Kaplan-Meier estimate of overall survival at 36 months was 26·4% (95% CI 14·3–40·1) for treatment naive patients and 19·0% (15·0–23·4) for previously treated patients, with median overall survival of 22·3 months (95% CI 17·1–31·5) and 10·5 months (8·6–13·2). PD-L1 tumour proportion score ≥50% was associated with longer median overall survival (95% CI) versus tumour proportion score 1–49% (treatment naive: 34·9 [20·3–not reached] vs 19·5 [10·7–26·3] months; previously treated: 15·4 [10·5–18·5] vs 8·5 [6·0–12·7] months). Grade 3–5 treatment-related adverse events occurred in 66 patients (12%), and 30 (6%) discontinued owing to a treatment-related adverse event. The most frequent grade 3–4 treatment-related adverse events were pneumonitis (10 [2%] of 550) and fatigue (5 [1%] of 550). Overall, 227 patients (41%) of 550 had serious adverse events, of which 50 (9%) were treatment related. Interpretation: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1. Funding: Merck Sharp & Dohme Corp.

Original languageEnglish (US)
Pages (from-to)347-357
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume7
Issue number4
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Survival
Random Allocation
Ligands
Safety
pembrolizumab
Research Personnel
Kaplan-Meier Estimate
Disease-Free Survival
Fatigue
Neoplasms
Pneumonia
Appointments and Schedules
Monoclonal Antibodies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001) : 3-year results from an open-label, phase 1 study. / Leighl, Natasha B.; Hellmann, Matthew D.; Hui, Rina; Carcereny, Enric; Felip, Enriqueta; Ahn, Myung Ju; Eder, Joseph Paul; Balmanoukian, Ani S.; Aggarwal, Charu; Horn, Leora; Patnaik, Amita; Gubens, Matthew; Ramalingam, Suresh S.; Lubiniecki, Gregory M.; Zhang, Jin; Piperdi, Bilal; Garon, Edward B.

In: The Lancet Respiratory Medicine, Vol. 7, No. 4, 01.04.2019, p. 347-357.

Research output: Contribution to journalArticle

Leighl, NB, Hellmann, MD, Hui, R, Carcereny, E, Felip, E, Ahn, MJ, Eder, JP, Balmanoukian, AS, Aggarwal, C, Horn, L, Patnaik, A, Gubens, M, Ramalingam, SS, Lubiniecki, GM, Zhang, J, Piperdi, B & Garon, EB 2019, 'Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study', The Lancet Respiratory Medicine, vol. 7, no. 4, pp. 347-357. https://doi.org/10.1016/S2213-2600(18)30500-9
Leighl, Natasha B. ; Hellmann, Matthew D. ; Hui, Rina ; Carcereny, Enric ; Felip, Enriqueta ; Ahn, Myung Ju ; Eder, Joseph Paul ; Balmanoukian, Ani S. ; Aggarwal, Charu ; Horn, Leora ; Patnaik, Amita ; Gubens, Matthew ; Ramalingam, Suresh S. ; Lubiniecki, Gregory M. ; Zhang, Jin ; Piperdi, Bilal ; Garon, Edward B. / Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001) : 3-year results from an open-label, phase 1 study. In: The Lancet Respiratory Medicine. 2019 ; Vol. 7, No. 4. pp. 347-357.
@article{0ff7ca95d6b0452b875dc5ab70f44a9c,
title = "Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study",
abstract = "Background: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001. Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated randomisation schedule at cohort-dependent ratios, and a further four cohorts were assigned to a pembrolizumab dose without randomisation. We present 3-year outcomes for the full analysis set of patients who received at least one dose of study treatment, pooled for all pembrolizumab doses. The primary efficacy endpoint was proportion of patients with objective response, analysed here as investigator-assessed response according to immune-related response criteria. Secondary efficacy endpoints included overall survival, duration of response, and progression-free survival. Safety endpoints included incidence of adverse events. This study is registered at ClinicalTrials.gov, number NCT01295827, and is ongoing. Findings: Between May 8, 2012 and July 13, 2014, 550 patients (101 treatment naive and 449 previously treated) were enrolled. Median follow-up was 34·5 months at data cutoff (Sept 1, 2016). At 36 months, investigator-assessed objective response according to immune-related response criteria was achieved for 41 of 101 treatment naive patients (41{\%} [95{\%} CI 30·9–50·8]; median duration of response was 16·7 months [95{\%} CI 12·6–not reached]) and 102 of 449 previously treated patients (23{\%} [18·9–26·9]; 33·3 ([22·5–not reached]). The Kaplan-Meier estimate of overall survival at 36 months was 26·4{\%} (95{\%} CI 14·3–40·1) for treatment naive patients and 19·0{\%} (15·0–23·4) for previously treated patients, with median overall survival of 22·3 months (95{\%} CI 17·1–31·5) and 10·5 months (8·6–13·2). PD-L1 tumour proportion score ≥50{\%} was associated with longer median overall survival (95{\%} CI) versus tumour proportion score 1–49{\%} (treatment naive: 34·9 [20·3–not reached] vs 19·5 [10·7–26·3] months; previously treated: 15·4 [10·5–18·5] vs 8·5 [6·0–12·7] months). Grade 3–5 treatment-related adverse events occurred in 66 patients (12{\%}), and 30 (6{\%}) discontinued owing to a treatment-related adverse event. The most frequent grade 3–4 treatment-related adverse events were pneumonitis (10 [2{\%}] of 550) and fatigue (5 [1{\%}] of 550). Overall, 227 patients (41{\%}) of 550 had serious adverse events, of which 50 (9{\%}) were treatment related. Interpretation: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1. Funding: Merck Sharp & Dohme Corp.",
author = "Leighl, {Natasha B.} and Hellmann, {Matthew D.} and Rina Hui and Enric Carcereny and Enriqueta Felip and Ahn, {Myung Ju} and Eder, {Joseph Paul} and Balmanoukian, {Ani S.} and Charu Aggarwal and Leora Horn and Amita Patnaik and Matthew Gubens and Ramalingam, {Suresh S.} and Lubiniecki, {Gregory M.} and Jin Zhang and Bilal Piperdi and Garon, {Edward B.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/S2213-2600(18)30500-9",
language = "English (US)",
volume = "7",
pages = "347--357",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001)

T2 - 3-year results from an open-label, phase 1 study

AU - Leighl, Natasha B.

AU - Hellmann, Matthew D.

AU - Hui, Rina

AU - Carcereny, Enric

AU - Felip, Enriqueta

AU - Ahn, Myung Ju

AU - Eder, Joseph Paul

AU - Balmanoukian, Ani S.

AU - Aggarwal, Charu

AU - Horn, Leora

AU - Patnaik, Amita

AU - Gubens, Matthew

AU - Ramalingam, Suresh S.

AU - Lubiniecki, Gregory M.

AU - Zhang, Jin

AU - Piperdi, Bilal

AU - Garon, Edward B.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001. Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated randomisation schedule at cohort-dependent ratios, and a further four cohorts were assigned to a pembrolizumab dose without randomisation. We present 3-year outcomes for the full analysis set of patients who received at least one dose of study treatment, pooled for all pembrolizumab doses. The primary efficacy endpoint was proportion of patients with objective response, analysed here as investigator-assessed response according to immune-related response criteria. Secondary efficacy endpoints included overall survival, duration of response, and progression-free survival. Safety endpoints included incidence of adverse events. This study is registered at ClinicalTrials.gov, number NCT01295827, and is ongoing. Findings: Between May 8, 2012 and July 13, 2014, 550 patients (101 treatment naive and 449 previously treated) were enrolled. Median follow-up was 34·5 months at data cutoff (Sept 1, 2016). At 36 months, investigator-assessed objective response according to immune-related response criteria was achieved for 41 of 101 treatment naive patients (41% [95% CI 30·9–50·8]; median duration of response was 16·7 months [95% CI 12·6–not reached]) and 102 of 449 previously treated patients (23% [18·9–26·9]; 33·3 ([22·5–not reached]). The Kaplan-Meier estimate of overall survival at 36 months was 26·4% (95% CI 14·3–40·1) for treatment naive patients and 19·0% (15·0–23·4) for previously treated patients, with median overall survival of 22·3 months (95% CI 17·1–31·5) and 10·5 months (8·6–13·2). PD-L1 tumour proportion score ≥50% was associated with longer median overall survival (95% CI) versus tumour proportion score 1–49% (treatment naive: 34·9 [20·3–not reached] vs 19·5 [10·7–26·3] months; previously treated: 15·4 [10·5–18·5] vs 8·5 [6·0–12·7] months). Grade 3–5 treatment-related adverse events occurred in 66 patients (12%), and 30 (6%) discontinued owing to a treatment-related adverse event. The most frequent grade 3–4 treatment-related adverse events were pneumonitis (10 [2%] of 550) and fatigue (5 [1%] of 550). Overall, 227 patients (41%) of 550 had serious adverse events, of which 50 (9%) were treatment related. Interpretation: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1. Funding: Merck Sharp & Dohme Corp.

AB - Background: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001. Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated randomisation schedule at cohort-dependent ratios, and a further four cohorts were assigned to a pembrolizumab dose without randomisation. We present 3-year outcomes for the full analysis set of patients who received at least one dose of study treatment, pooled for all pembrolizumab doses. The primary efficacy endpoint was proportion of patients with objective response, analysed here as investigator-assessed response according to immune-related response criteria. Secondary efficacy endpoints included overall survival, duration of response, and progression-free survival. Safety endpoints included incidence of adverse events. This study is registered at ClinicalTrials.gov, number NCT01295827, and is ongoing. Findings: Between May 8, 2012 and July 13, 2014, 550 patients (101 treatment naive and 449 previously treated) were enrolled. Median follow-up was 34·5 months at data cutoff (Sept 1, 2016). At 36 months, investigator-assessed objective response according to immune-related response criteria was achieved for 41 of 101 treatment naive patients (41% [95% CI 30·9–50·8]; median duration of response was 16·7 months [95% CI 12·6–not reached]) and 102 of 449 previously treated patients (23% [18·9–26·9]; 33·3 ([22·5–not reached]). The Kaplan-Meier estimate of overall survival at 36 months was 26·4% (95% CI 14·3–40·1) for treatment naive patients and 19·0% (15·0–23·4) for previously treated patients, with median overall survival of 22·3 months (95% CI 17·1–31·5) and 10·5 months (8·6–13·2). PD-L1 tumour proportion score ≥50% was associated with longer median overall survival (95% CI) versus tumour proportion score 1–49% (treatment naive: 34·9 [20·3–not reached] vs 19·5 [10·7–26·3] months; previously treated: 15·4 [10·5–18·5] vs 8·5 [6·0–12·7] months). Grade 3–5 treatment-related adverse events occurred in 66 patients (12%), and 30 (6%) discontinued owing to a treatment-related adverse event. The most frequent grade 3–4 treatment-related adverse events were pneumonitis (10 [2%] of 550) and fatigue (5 [1%] of 550). Overall, 227 patients (41%) of 550 had serious adverse events, of which 50 (9%) were treatment related. Interpretation: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1. Funding: Merck Sharp & Dohme Corp.

UR - http://www.scopus.com/inward/record.url?scp=85063304086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063304086&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(18)30500-9

DO - 10.1016/S2213-2600(18)30500-9

M3 - Article

VL - 7

SP - 347

EP - 357

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 4

ER -